Medical patients regularly present with complicated multi-pathologies, often involving more than one system, each having a significant impact on the others. This chapter looks at some of the more common pathologies that the on call physiotherapist will encounter, highlighting important points to consider when assessing and treating the medical patient.

COPD {#cesec1}
====

COPD exacerbations may be idiopathic or caused by bacterial or viral infection. Hypoxaemia will be the primary reason for the call out and the aim of physiotherapy is to establish the cause of hypoxaemia and treat as appropriate.

Major causes of hypoxaemia in COPD exacerbation include:•Bronchospasm•Sputum retention•Consolidation.

Others common causes include:•Cardiac event•Pneumothorax•Pulmonary embolus.

CONTROLLED OXYGEN THERAPY AND COPD {#cesec2}
==================================

Oxygen is a drug and should be prescribed. Prescription should include percentage, flow rate, delivery device and whether oxygen delivery is intermittent or continuous. Any changes to oxygen therapy should be discussed with medical staff. Prescription may be flexible, for example 'maintain sats between 88% and 92%', in which case the FiO~2~ can be changed as necessary until the desired saturation is reached.

NB: Liaise with medical staff to establish target SpO~2~ levels for each individual patient. They may be as low as 80--85% in chronically hypoxic patients.

The role of the physiotherapist in relation to oxygen therapy includes:•Assessment of oxygenation prior to, during and following treatment•Ensuring the patient is receiving oxygen as prescribed•Informing medical staff of increasing oxygen requirements•Humidification of FiO~2~ \>30% (or lower if secretions are tenacious).

Some patients with COPD are classified as oxygen sensitive and have a chronically raised PaCO~2~. They rely on a low PaO~2~ to stimulate breathing, rather than an altered pH. This is called *hypoxic drive*. If too much oxygen is given, their stimulus to breathe (low PaO~2~) is removed and the patient stops breathing, resulting in type II respiratory failure, sometimes called *oxygen-induced respiratory acidosis*.

It is vital that all COPD patients receive *controlled oxygen therapy* until it is established whether they are oxygen sensitive (through arterial blood gas analysis).

BEST PRACTICE FOR INITIAL USE OF SUPPLEMENTAL OXYGEN THERAPY IN COPD ([@bib3]) {#cesec3}
==============================================================================

•Maintain adequate O~2~ levels (saturations ≥90%) without precipitating respiratory acidosis or worsening hypercapnia.•Deliver O~2~ via a controlled system such as a Venturi device. If a mask is not tolerated O~2~ may be delivered via nasal cannulae.•Until it is established whether a COPD patient is O~2~ sensitive, start FiO~2~ at 0.28 and increase until PaO~2~ is \>7.6 kPa, without causing a significant fall in pH.•The COPD patient with respiratory acidosis, despite optimal medical management and controlled oxygen therapy, will require NIV or IPPV.•If the COPD patient is not O~2~ sensitive, increase FiO~2~ until saturations are ≥90%.

MANAGEMENT OF THE COPD PATIENT WITH RESPIRATORY ACIDOSIS REQUIRING NIV ([@bib2] {#cesec4}
===============================================================================

(Refer to Chapter 9.)•Only consider NIV following optimal medical management and controlled O~2~ therapy.•COPD patients are at risk of pneumothorax with positive pressure ventilation.•Use controlled O~2~ therapy when removing from NIV.

CAUSES OF READMISSION IN COPD {#cesec5}
=============================

Physiotherapy can play an important role in establishing the cause of frequent admissions in some patients and in helping to prevent such admissions ([Table 12.1](#cetable1){ref-type="table"} ).Table 12.1Common causes of readmission in the COPD patientCauseAdviceUncontrolled symptoms•Optimize medical therapy•Shortness of breath•Teach techniques for mastery of breathlessness•Assess need for short-burst or ambulatory oxygen therapy•Sputum retention•Assist sputum clearance without impacting on breathlessness•Consider whether mucolytics may be beneficialRecurrent need for NIV•Patients with late-stage COPD may require domiciliary NIV to prevent relapse into type II respiratory failureAnxiety or depression•Be alert to depression in COPD patients who are hypoxic (SpO~2~ \<92%), have severe dyspnoea, or have been admitted with exacerbation

CARE OF THE PATIENT WITH END-STAGE COPD {#cesec6}
=======================================

It is important to establish the ceiling of treatment agreed by the patient, their family and their medical team. IPPV may be deemed futile, and the fully informed patient may decide that NIV is not in their best interest; treatment may consist solely of medications and physiotherapy.

Assess the patient and formulate your plan and goals in line with what the patient wishes to achieve. There may be some disparity between what you perceive as optimal treatment and what the patient consents to. Some patients may wish to limit treatment to symptom control while others may feel that any intervention will worsen shortness of breath, outweighing any benefits gained, and thus decline what physiotherapy has to offer. These patients, who have had years of coping with unpleasant and disabling symptoms and have often had multiple inpatient admissions, are able to make truly informed choices.

Patients with end-stage COPD, together with their families and carers, should have access to the full range of services offered by the multidisciplinary palliative care teams, including admission to hospices. Opioids, benzodiazepines, tricyclic antidepressants and oxygen therapy may be used for the palliation of breathlessness in patients unresponsive to other medical treatments. In the terminal stages of the disease, antisecretory agents may be useful.

ACUTE ASTHMA {#cesec7}
============

Optimal medical management is essential during acute exacerbation of asthma and may include magnesium infusion, inhaled or nebulized bronchodilators (beta-2 agonists and antimuscarinics), inhaled, nebulized, oral or intravenous corticosteroids, and theophyllines. Antibiotics will be used if there is evidence of infection (↑white cell count, neutrophils and CRP, ± pyrexia) ([Table 12.2](#cetable2){ref-type="table"} ).Table 12.2Common issues in the treatment of patients with acute asthmaCommon issuesAdviceBronchospasm•Be calm•Ensure adequate, humidified O~2~. Heated humidification may be necessary. Cold water humidification may exacerbate bronchospasm•Treat ½ hour post bronchodilators if possible•Re-assess regularly and discontinue treatment if bronchospasm worsens•ACBT•Avoid repeated huffing or coughing -- it may worsen bronchospasm•Emphasize periods of breathing control•Remember manual techniques may ↑ bronchospasmSputum plugsSticky plugs or casts of sputum are common. These may cause plugging off of major airways, leading to lobar collapse•Ensure O~2~ is humidified•Consider mucolytics•Encourage oral or i.v. fluids if patient shows signs of dehydration•Slow, single-handed percussion may be useful providing it does not increase bronchospasm•See Chapter 6The tiring patientInspiratory *[and]{.ul}* expiratory polyphonic wheeze or a silent chest on auscultation are signs of deteriorating asthmaBeware of 'normal' blood gases. Initially patients show type I respiratory failure ± hypocapnia. As they tire, pCO~2~ rises, but ABGs may have been taken as pCO~2~ is rising through the normal range. Look for signs of CO~2~ retention/narcosis (see Chapter 9)•If you suspect the patient is deteriorating, ask for an urgent medical review•Use positioning to optimize respiratory muscle function and reduce work of breathing•Only use sputum clearance techniques if you think sputum retention is significant in causing airway obstruction (refer to Chapter 6)•Avoid tiring patient further. Restrict to short, regular treatments•Non-invasive or invasive ventilation will be required for patients with type 2 respiratory failure (refer to Chapter 9)•*! NB: Check for pneumothorax before applying non-invasive ventilation* (refer to CXR and auscultation sections)

PANCREATITIS {#cesec8}
============

Pancreatitis can be acute (one-off occurrence), chronic where it persists even after the cause has been removed, or hereditary. Causes include gallstones, excessive alcohol consumption, hypertriglyceridaemia, viral infection, trauma, vasculitis or pregnancy.

The aim of physiotherapy is to identify and treat the cause of hypoxaemia ([Table 12.3](#cetable3){ref-type="table"} ).Table 12.3Common issues in the management of the medical patient with pancreatitisCommon issues/complicationsAdvice**Pain**Severe upper abdominal pain radiating to the back causing ↓TV and atelectasis•Ensure adequate analgesia prior to treatmentOpiates may reduce respiratory drive•Check respiratory rate. If \<12 b.p.m., discuss alternative forms of analgesia with teamLobar or lung collapse is common as a consequence of upper abdominal pain*NB*: ↓*BS may be due to pleural effusion, also commonly seen in pancreatitis* (see sections on respiratory assessment and CXR)•See Chapter 7**Distended abdomen**Limits diaphragmatic excursion leading to volume loss•Position patient to allow free movement of diaphragm•See Chapter 7**Hypoxaemia**As a consequence of:Volume loss•See Chapter 7Acute pneumonitis•May require high-flow, heated humidified O~2~ therapy. CPAP may be indicatedPancreatic enzymes may directly damage the lungs•Physiotherapy cannot improve the underlying process, but assess for sputum retention and use positioning to alleviate SOB/↓WOBARDSSIRS and multi-organ dysfunction syndrome are known complications of pancreatitis. Signs and symptoms of ARDS include ↑O~2~ requirement, hypoxaemia refractory to O~2~ therapy, tachypnoea and non-cardiogenic pulmonary oedemaAspiration pneumoniaVomiting is common with pancreatitis. Look for signs of sudden respiratory distress following a history of vomiting. Often affects the right middle or lower lobe•Humidify high-flow oxygen•CPAP may be indicated•Patients commonly require intubation and ventilation•Physiotherapy is of limited benefit•*Prompt treatment will limit pneumonitis*•Use postural drainage if appropriate, manual techniques and ACBT to mobilize aspirate. Clear with FET, cough or suction**Dehydration**Common as a result of vomiting and internal bleeding•Assess fluid balance and observation charts. Urea will be raised (with normal creatinine) in the dehydrated patient (see glossary of normal values)•Electrolyte disturbance is possible with vomiting. Check blood results prior to treatment•Ensure CVS stability prior to treatment•Humidify O~2~ therapy**Sepsis**ARDS is a manifestation of SIRS•Look for cardiovascular implications of sepsis -- low BP, high HR•Report worsening signs of sepsis/ARDS: Increasing O~2~ requirement or RR, decreasing BP or increasing HR, cardiovascular instability. Use early warning system, e.g. MEWS, if utilized by your Trust

TREATMENT OF THE RENAL PATIENT {#cesec9}
==============================

Renal failure is characterized by raised urea and creatinine levels. Electrolytes may also become deranged ([Tables 12.4,](#cetable4){ref-type="table"} [12.5](#cetable5){ref-type="table"} and [12.6](#cetable6){ref-type="table"} ).Table 12.4Common issues in the management of the patient with renal failureCommon issuesAdvice**Tachypnoea**May be due to respiratory compensation of metabolic acidosisAcute renal failure may result in oliguria leading to CCF, pulmonary oedema and pleural effusions•Physiotherapy is of limited benefit unless there is evidence of co-existing respiratory complications**Tenacious sputum**Renal patients may be fluid restricted and will be receiving diuretic therapy/dialysis•Humidify O~2~•Encourage fluids if allowed**Altered mental state/confusion/seizures**Altered mental state may be due to hypoxaemia, deranged electrolytes or changes in pH•Assess whether SpO~2~ is low•Ensure O~2~ is delivered as prescribed•Liaise with medical staff if O~2~ requirement increased•May be difficult to gain informed consent. Treat in patient\'s best interestTable 12.5Common issues when treating the patient with chronic or acute-on-chronic renal failureCommon issuesAdviceOsteoporosis•Check CXR for signs of fractures•Ensure adequate analgesia prior to treatment•Care with manual techniquesAnaemia•Check Hb prior to treatment (refer to glossary of normal values in Appendix 2)•Patients may be tissue hypoxic with normal SaO~2~•May contribute to breathlessness↓Immune response/↓WCC•↑risk of opportunistic infection•Use reverse barrier methods in line with hospital protocolTable 12.6Causes of cardiovascular instability in the patient with renal failureCauseAdviceElectrolyte disturbance (risk of arrhythmia)•Check K^+^ and Ca^++^ levels prior to treatment (refer to glossary of normal values in Appendix 2)•If deranged, check imbalance is being treated or contact the teamCardiac tamponade and pericarditis•Establish diagnosis from notes•Examine observation charts and ensure CVS stability prior to treatment•Liaise with nursing staff regarding response to handlingPatients on haemofiltration may be CVS unstable due to rapid changes in fluid status•Examine observation charts•Liaise with nursing staff

OESOPHAGEAL VARICES {#cesec10}
===================

Oesophageal varices are extremely dilated submucosal veins in the oesophagus. They are a consequence of portal hypertension as seen in liver cirrhosis. They are very likely to bleed and are diagnosed via endoscopy ([Table 12.7](#cetable7){ref-type="table"} ).Table 12.7Common issues when treating patients with oesophageal varicesCommon issuesAdviceActively bleeding oesophageal varices•**All physiotherapy is contraindicated**Deranged clotting•**Suction is contraindicated**•Care with manual techniques and coughing•Utilize ACBT with huffing, positioning and mobilization to assist sputum clearance and prevent respiratory complications**NB: Do not use postural drainage or positive pressure treatments with these patients**Treated oesophageal varices•**Suction and postural drainage remain contraindicated**

INTERSTITIAL LUNG DISEASE {#cesec11}
=========================

Interstitial lung disease (ILD) refers to a group of lung diseases characterized by inflammation which often leads to pulmonary fibrosis. Fibrosis destroys the alveoli, interstitium and capillary network of the affected areas of lung resulting in a restrictive disorder ([Table 12.8](#cetable8){ref-type="table"} ).Table 12.8Common issues when treating patients with pulmonary fibrosisCommon issuesAdvice**Dry, irritating cough**•Physiotherapy is not indicated unless there is a superimposed respiratory tract infection**Fatigue**•Discuss energy conservation and pacing**SOB**Profoundly ↓lung compliance in fibrotic lung disease causes extreme SOB on exertion and eventually at rest. It can be extremely distressing•Reassure +++•Teach positions of ease to optimize respiratory muscle function and reduce WOB•Pharmaceutical palliation of breathlessness is necessary in end-stage disease (see palliative care for COPD patient above)**Severe hypoxaemia**At rest:Fibrosis slows diffusion of O~2~ across the respiratory membrane (diffusion defect)•Ensure adequate FiO~2~ is being delivered by monitoring SpO~2~•Keep O~2~ mask on throughout treatment•Humidify FiO~2~ \>30%•CPAP is often required to maintain oxygenation•If type II respiratory failure develops, NIV or invasive ventilation will be required, if appropriate**NB: Higher pressures will be required to ventilate 'stiff lungs' so** ↑**risk of pneumothorax**On exertion:Exertion speeds up pulmonary blood flow resulting in even less time for Hb to be oxygenated. This can cause extreme dips in SpO~2~•Monitor SpO~2~ closely during treatment•Always ensure adequate O~2~ delivery when moving the fibrotic patient. An ↑FiO~2~ will probably be required•Dips in SpO~2~ and breathlessness on exertion will resolve with rest and O~2~ therapy. Be patient. It may take several minutes

PNEUMONIA {#cesec12}
=========

Pneumonia results from an inflammation of the alveolar space, usually due to invasion by bacteria, viruses or fungi, or as a result of chemical or physical injury. In bacterial and fungal infection, alveoli fill with protein-rich fluid and debris from white blood cells. Sputum production also increases ([Table 12.9](#cetable9){ref-type="table"} ).Table 12.9Management of patients with pneumoniaType of pneumoniaAdvice**Bronchopneumonia**Typically caused by bacteriaConsolidation is patchy involving one or more lobes, usually dependent lung zones. Exudate (consolidation) is centred in the bronchi and bronchioles with spread to adjacent alveoli. May progress to lobar pneumoniaAspiration causes an initial pneumonitis which often leads to bronchopneumoniaRML and RLL are most commonly affected. Prompt removal of aspirate will limit pneumonitis and the risk of bacterial pneumonia•Ensure adequate, humidified O~2~ therapy•Use sputum clearance techniques including ACBT, manual techniques and positioning as indicated•Consider saline nebulizers or mucolytics sputum tenacious•Use chest X-ray to determine affected lobes. Use PD to drain the affected areas. *Remember each lobe has several segments*•Consider suction or cough-assist in those patients unable to cough effectively**Lobar/multilobar pneumonia**Consolidation in one or more lobes Typically caused by bacterial infection•Ensure adequate, humidified O~2~ therapyPosition to optimize V/Q matching and therefore arterial oxygenation (down with the good lung in unilateral disease)•Further physiotherapy is not indicated in non-productive, fully consolidated pneumonia•Re-assess daily and use sputum clearance techniques if patient has a productive cough. See Chapter 6Interstitial pneumoniaOften caused by viruses or atypical bacteria. Viral pneumonia may make patient more susceptible to superimposed bacterial pneumonia•Physiotherapy not indicated unless evidence of bacterial infection**Fungal pneumonia**Commonly affects immunosuppressed patients. Includes *Pneumocystis jiroveci* (previously called *P. carinii* pneumonia or PCP).•Ensure O~2~ therapy is humidified•Position to ↓WOB•Severely hypoxaemic patients will require CPAPCan cause extreme hypoxaemia and rapid onset of type I and II respiratory failure. Non-productive in early stages•Patients in type II respiratory failure will require NIV or IPPV•Further physiotherapy not indicated unless evidence of sputum retention•You may be asked for an induced sputum specimen for diagnosis of *P. jiroveci*. This is not an on call procedure**Pandemic pneumonia**Includes:SARS (severe acute respiratory syndrome), caused by the coronavirusHighly contagious and mortality is highLast seen in China in 2003Primary viral pneumonia and secondary bacterial pneumonia as a consequence of pandemic influenza•Follow your local hospital infection control guidelines for pandemic pneumonia•Only treat those patients who have evidence of sputum retention. Treat as presents, i.e. bronchopneumonia or lobar pneumonia (see above)

Interstitial pneumonia is characterized by patchy or diffuse inflammation of the interstitium (the area between the alveoli). The alveoli do *not* contain significant exudate.

CYSTIC FIBROSIS (ADULT) {#cesec13}
=======================

Adult cystic fibrosis (CF) patients will have their own independent airway clearance regime. It may comprise of PD ± self-percussion and ACBT, PEP mask, Flutter device or the Acapella. You do not need to be an expert in all these techniques, but during infective exacerbation you need to assess the effectiveness of the normal regime, and assist with sputum clearance if necessary. Patients may benefit from PD and manual techniques performed by the physiotherapist. It is advisable to do one or two lung areas with each treatment. Treatment may need to be further modified in the patient with dyspnoea, e.g. modified PD, ↑emphasis on breathing control ([@bib1] ([Table 12.10](#cetable10){ref-type="table"} ).Table 12.10Common issues in the treatment of adult CF patientsCommon issuesAdvice**Haemoptysis**Blood streakingModerate haemoptysisFrank haemoptysis•Treat as normal•Use TEEs and gentle huffing only. Minimize coughing•Discontinue physiotherapy until bleeding settles. Humidify O~2~**Type I respiratory failure**Hypoxaemic episodes will become more common as disease progresses•Ensure adequate, humidified O~2~ therapy. Heated humidification may be necessary with thick secretions•Effective sputum clearance will decrease airway obstruction and improve oxygenation. Check SpO~2~ pre and post treatment•Monitor SpO~2~ and modify treatment if it causes significant dips, e.g. modify PD positions, limit periods of huffing, ↑emphasis on breathing control, salbutamol nebulizer pre or post treatment**Type II respiratory failure**NIV may be used as a bridge to lung or heart/lung transplant. Patients may have domiciliary NIV (for overnight use or more prolonged periods) and are likely to be confident with its use•NIV or IPPV will be required for patients in type II respiratory failure•Treat patients on NIV with their mask on, removing it to allow expectoration•A nasal mask may be more suitable for those with copious secretions•Monitor saturations throughout treatment•This should not influence physiotherapy management•**NB: CF patients have an ↑risk of pneumothorax with positive pressure techniques** (See Chapters 5 and 19)**Infection control**•Always treat patients with MRSA, *Pseudomonas aeruginosa* or *Burkholderia cepacia* last if possible•Ensure strict hand hygiene and follow local hospital guidelines for infection control**Osteoporosis**CF patients often have poor uptake of vitamin D which can lead to osteoporosis•Use caution with manual techniques•Ensure adequate pain relief prior to treatment if necessary**Liver disease**This is common in the later stages of CFAscites will impinge on the diaphragm causing volume lossLiver disease may cause portal hypertension leading to oesophageal varices•Position patient to allow free movement of the diaphragm (see Chapter 7)•These patients will not tolerate headdown tilts•Treatment with the Acapella, Flutter device or PEP mask may be more appropriate•See previous section on oesophageal varices**Terminal stages of CF**Not all patients want, or are suitable for, transplant. This is an extremely distressing time for both the patient and their family. Patients should have access to bereavement counsellors and the palliative care team who will manage their symptoms•Treat for comfort only, at the patient\'s request

BRONCHIECTASIS {#cesec14}
==============

Bronchiectasis is the abnormal dilatation of bronchi caused by destruction of muscular and elastic components of the bronchial walls. The airways lose their normal sputum clearance mechanisms. Causes include TB, pertussis, measles, aspiration of a foreign body or severe bacterial pneumonia (often in childhood). It is an obstructive lung disease and usually affects one or more lobes (commonly the lower lobes). Signs and symptoms include chronic purulent sputum production (sometimes several cupfuls a day), regular and often persistent respiratory tract infections, chronic cough, disturbed sleep, fatigue and finger clubbing. Bronchiectatic patients, like CF patients, usually have their own airway clearance regime. It may comprise of PD ± self-percussion and ACBT, PEP mask, Flutter device or the Acapella (see CF section above). In acute infective exacerbation they may require assistance to achieve effective sputum clearance. Common issues include type I respiratory failure, haemoptysis and infection control (see [Table 12.10](#cetable10){ref-type="table"}). In the later stages of the disease, patients may admit with type II respiratory failure requiring NIV or IPPV (see Chapter 9).
